文献速递细胞病理与分子病理神经与头颈病理

甲状腺结节AUS亚型与Afirma基因表达分类器结果及临床结局的关联

Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
PubMed 文献 · Cancer Cytopathol · 2017-02-02

该回顾性研究纳入227个细针穿刺细胞学为意义未明的不典型(AUS)且接受Afirma基因表达分类器(GEC)检测的甲状腺结节,比较结构异型(AUS-A)、细胞异型(AUS-C)及两者兼有(AUS-C/A)三类结节的GEC良性与恶性结果及临床结局。结果显示GEC良性率在AUS-A最高、AUS-C/A最低,GEC可疑结节中癌症风险AUS-C/A最高。

要点

  • AUS-A结节GEC良性率65%,高于AUS-C/A的38%(P=.0008),AUS-C为59%。
  • GEC可疑且多数行切除的结节中,癌症风险AUS-A为19%、AUS-C/A为57%(P=.003)、AUS-C为45%(P=.07)。
  • AUS的细胞学异型限定词不同,Afirma GEC的表现与恶性风险随之不同,可用于更精准的咨询与治疗建议。

核心结论

  • Afirma GEC检测的表现特征随细胞学异型限定词不同而变化,识别这些差异有助于临床医生提供更好的咨询与治疗建议。

研究设计与样本

  • 回顾性综述,纳入作者所在机构4年余内所有细胞学为AUS并接受Afirma GEC检测的甲状腺结节,共227个结节。

主要发现

  • AUS-A结节GEC良性率为65%(70/107),高于AUS-C/A的38%(25/65),差异有统计学意义(P=.0008)。
  • AUS-C结节GEC良性率为59%(27/55),介于两者之间。
  • GEC可疑结节中86%接受切除,其癌症风险AUS-A为19%(6/25),AUS-C/A为57%(21/37),差异有统计学意义(P=.003)。
  • AUS-C结节在GEC可疑者中的癌症风险为45%(10/22),与AUS-A比较P=.07。
  • 重复细胞学仍为不确定结果的结节,其GEC良性率与恶性率与单次细胞学结果结节相比未见差异。

关键数值与推荐

  • AUS-A:GEC良性70/107(65%);GEC可疑者癌症风险6/25(19%)。
  • AUS-C/A:GEC良性25/65(38%),与AUS-A比较P=.0008;GEC可疑者癌症风险21/37(57%),与AUS-A比较P=.003。
  • AUS-C:GEC良性27/55(59%);GEC可疑者癌症风险10/22(45%),与AUS-A比较P=.07。
  • GEC可疑结节中86%接受了切除。

临床怎么用

  • 对细胞学AUS结节可按结构异型、细胞异型或两者兼有分层解读Afirma GEC结果,并据此调整恶性风险评估与咨询。
  • AUS-C/A且GEC可疑者恶性风险较高,AUS-A且GEC良性者风险较低,可辅助治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thyroid nodules with atypia of undetermined significance (AUS) on fine-needle aspiration (FNA) have a low risk of malignancy that appears to vary based on specific features described in the AUS diagnosis. The Afirma gene expression classifier (GEC) is a molecular test designed to improve preoperative risk stratification of thyroid nodules, but its performance for different patterns of AUS has not been defined. The objective of this study was to assess GEC results and clinical outcomes in AUS nodules with architectural atypia (AUS-A), cytologic atypia (AUS-C) or both (AUS-C/A). METHODS: This was a retrospective review of all thyroid nodules with AUS cytopathology that underwent GEC testing at the authors' institution over a period of >4 years. RESULTS: In 227 nodules that had AUS cytology results and Afirma GEC testing, the rate of benign GEC results was higher in AUS-A nodules (70 of 107; 65%) than in AUS-C/A nodules (25 of 65; 38%; P = .0008), and AUS-C nodules exhibited an intermediate rate of benign results (27 of 55 nodules; 59%). The risk of cancer among patients who had GEC-suspicious nodules, 86% of whom underwent resection, was 19% (6 of 25) for AUS-A nodules compared with 57% (21 of 37) for AUS-C/A nodules (P = .003) and 45% (10 of 22) for AUS-C nodules (P = .07). In nodules that had an indeterminate repeat cytology result, no difference was observed in the rate of benign GEC results or in the malignancy rate compared with nodules that had a single cytology result. CONCLUSIONS: The performance characteristics of Afirma GEC testing vary, depending on qualifiers of cytologic atypia. Recognition of these differences may enable clinicians to provide improved counseling and treatment recommendations to patients. Cancer Cytopathol 2017;125:313-322. © 2017 American Cancer Society.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Baca SC, Wong KS, Strickland KC, et al. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes. Cancer Cytopathol. 2017. PMID: 28152275. doi:10.1002/cncy.21827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。